Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly & Co. closed 20.65% short of its 52-week high of $972.53, which the company achieved on August 22nd.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...